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Clinical Study
Antitumour activity of pembrolizumab in advanced mucosal
melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006
Omid Hamid1, Caroline Robert2, Antoni Ribas3, F. Stephen Hodi4, Euan Walpole5, Adil Daud6, Ana S. Arance7, Ewan Brown8,
Christoph Hoeller9, Laurent Mortier10, Jacob Schachter11, Jianmin Long12, Scot Ebbinghaus12, Nageatte Ibrahim12 and Marcus Butler13
BACKGROUND: Mucosal melanoma is an aggressive melanoma with poor prognosis. We assessed efficacy of pembrolizumab in
patients with advanced mucosal melanoma in KEYNOTE-001 (NCT01295827), −002 (NCT01704287), and −006 (NCT01866319).
METHODS: Patients received pembrolizumab 2mg/kg every 3 weeks (Q3W) or 10 mg/kg Q2W or Q3W. Response was assessed
by independent central review per RECIST v1.1.
RESULTS: 1567 patients were treated and 84 (5%) had mucosal melanoma. Fifty-one of 84 were ipilimumab-naive. In patients with
mucosal melanoma, the objective response rate (ORR) was 19% (95% CI 11–29%), with median duration of response (DOR) of
27.6 months (range 1.1+ to 27.6). Median progression-free survival (PFS) was 2.8 months (95% CI 2.7–2.8), with median overall
survival (OS) of 11.3 months (7.7–16.6). ORR was 22% (95% CI 11–35%) and 15% (95% CI 5–32%) in ipilimumab-naive and
ipilimumab-treated patients.
CONCLUSION: Pembrolizumab provides durable antitumour activity in patients with advanced mucosal melanoma regardless
of prior ipilimumab.
British Journal of Cancer (2018) 119:670–674; https://doi.org/10.1038/s41416-018-0207-6
INTRODUCTION
Mucosal melanomas, a rare but aggressive subtype, represent
~1.3% of all melanoma diagnoses.1,2 Most occur in the head and
neck (50% of cases), anorectal (25%), and vulvovaginal (20%)
regions, and are more frequent in women aged 70–79 years.2 As
there are no specific treatment guidelines for patients with
advanced mucosal melanoma, therapies are the same as for
advanced nonmucosal melanoma. Historically, outcomes with
mucosal melanoma are poorer than cutaneous melanoma. This
has been attributed to initial presentation at a later stage, with an
estimated 5-year survival rate across early stage of 81%.3 In
patients with metastatic mucosal melanoma, the 5-year survival
rate is ~16%.4
Recent data suggest that anti-PD-1 inhibitor therapies may
have antitumour activity against mucosal melanoma. In a phase
1 study of pembrolizumab in Japanese patients with advanced
melanoma, ORR was 25% and 24% for 8 patients with mucosal
and 29 with nonmucosal melanoma.5 In pooled analyses of
nivolumab and ipilimumab in 889 patients with advanced
melanoma (86 with mucosal melanoma), ORRs were 23 and 41%
in patients with mucosal and nonmucosal melanoma who
received nivolumab monotherapy, 37 and 60% in patients who
received nivolumab and ipilimumab combination therapy, and
8 and 21%, respectively, for patients who received ipilimumab
monotherapy.6
The monoclonal anti-PD-1 antibody pembrolizumab has
demonstrated robust and durable antitumour activity, with a
manageable safety profile in patients with ipilimumab-treated
and ipilimumab-naive advanced melanoma. Here, we report the
results of a post-hoc analysis assessing the efficacy of pembro-
lizumab in ipilimumab-naïve and ipilimumab-treated patients
with mucosal melanoma enrolled in the KEYNOTE-001, 002, and
006 clinical studies.7–9
MATERIALS AND METHODS
Patients
Eligibility criteria were previously reported.7–9 Common criteria
included age ≥18 years, histologically or cytologically confirmed,
unresectable stage III or IV melanoma, measurable disease per
Response Evaluation Criteria in Solid Tumour (RECIST) v1.1, Eastern
Cooperative Oncology Group performance status 0–1, and
adequate organ function. Patients receiving ≥ 1 dose of pembro-
lizumab are evaluated. Protocols for the studies were approved by
institutional review boards at each site. All patients provided
written informed consent.
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Treatment
In this exploratory, post-hoc analysis, data were pooled from three
studies of patients receiving pembrolizumab until disease
progression (PD) or unacceptable toxicity. KEYNOTE-001 was an
open-label, multicohort, phase 1b study of pembrolizumab 2mg/
kg Q3W, 10 mg/kg Q3W, or 10 mg/kg Q2W in adults with
ipilimumab-(PD-1 and PD-L1 inhibitor)-naive or treated, advanced
melanoma (N= 655); KEYNOTE-002 was an open-label, rando-
mised, phase 2 study of pembrolizumab 2mg/kg or 10 mg/kg
Q3W versus chemotherapy in adults with ipilimumab-refractory,
advanced melanoma (N= 540), and KEYNOTE-006 was an open-
label, randomised, phase 3 study of pembrolizumab 10mg/kg
Q3W or Q2W in ipilimumab-naive, advanced melanoma (N= 834).
Investigators were not required to indicate the location of the
primary mucosal melanoma lesion.
Efficacy assessments and statistical considerations
Response was assessed per RECIST v1.1 by independent central
review Q12W in KEYNOTE-001, at week 12 and every 6 weeks
through week 48, then Q12W thereafter in KEYNOTE-002 and
KEYNOTE-006. Survival was assessed Q12W in all studies.
Objectives included summarising baseline and disease character-
istics, evaluating ORR (complete response (CR)+ partial response
(PR)), disease control rate (DCR (CR+ PR+ stable disease (SD))),
duration of response (DOR): time from CR or PR to first PD,
progression-free survival (PFS): time from treatment start to first
PD or death, and overall survival (OS): time from treatment start
to death from any cause, in patients with advanced mucosal
melanoma, and assessment of ORR, DCR, PFS, and OS in patients
with mucosal and nonmucosal melanoma. PFS, OS, and DOR were
estimated using the Kaplan–Meier method.
RESULTS
Baseline characteristics
Eighty-four of 1567 (5%) patients receiving ≥ 1 dose of pembro-
lizumab had mucosal melanoma (Table 1); 36 of 655 (5%) in
KEYNOTE-001, 11 of 357 (3%) in KEYNOTE-002, and 37 of 555 (7%)
in KEYNOTE-006. Baseline characteristics between patients with
mucosal and nonmucosal melanoma were comparable including
age, ECOG performance status, stage M1c disease, presence
of liver metastases and prior ipilimumab. A larger proportion of
patients with mucosal melanoma had ≥ 2 prior therapies and
were PD-L1 negative (Table 1). Characteristics with ≥ 10% differ-
ence between the two groups included female sex (57% and 38%;
P= 0.0006), elevated LDH (48% and 36%; P= 0.0349), overall
baseline median tumour size ≥ 80.5 mm (58% and 43%; P=
0.0077), and BRAFV600 mutation (8 and 29%; P < 0.0001).
Efficacy
In patients with mucosal melanoma, ORR was 19% (95% CI
11–29%) overall, 22% (95% CI 11–35%) in ipilimumab-naive,
and 15% (95% CI 5–32%) in ipilimumab-treated patients (Fig. 1a).
ORRs were 13% (1 of 8) and 20% (15 of 76) in patients with
zero and ≥1 prior therapy, respectively. In nonmucosal melanoma,
ORR was 33% (95% CI 30–35%) overall, 38% (95% CI 34–41%)
in ipilimumab-naive, and 27% (95% CI 23–30%) in ipilimumab-
treated patients. ORRs were 42% (63 of 150) and 32% (421
of 1333) in patients with zero and ≥1 prior therapy, respectively.
The DCR was 31% (95% CI 21–42%) with 19% CR+ PR and 12%
SD for patients with mucosal and 47% (95% CI 44–49%) with 33%
CR+ PR and 14% SD for those with nonmucosal melanoma
(Fig. 1a).
For the 16 responders with mucosal melanoma, median time
to response was 2.8 months (range 2.6–19.4), and median DOR
was 27.6 months (range 1.1+months to 27.6 months) overall,
with 75% responses ongoing at the time of data cutoff (Fig. 1b).
For ipilimumab-naive patients (n= 11), median time to response
was 2.8 months (2.8–16.8) and median DOR was not reached
(range 2.8+ to 22.1+months) with 73% of responses ongoing.
For ipilimumab-treated patients (n= 5), median time to response
was 4.4 months (2.6–19.4) and median DOR was 27.6 months
(range 1.1+ to 27.6) with 80% of responses ongoing (Fig. 1b).
In the 484 responders with nonmucosal melanoma, median DOR
was not reached (range 1.3+ to 38.8+months), with 72%
of responses ongoing (Fig. 1b). Median DOR was 34.6 months
(range 1.3+ to 38.8+ ) for ipilimumab-naive patients (n= 307),
with 70% of responses ongoing, and was not reached (range 1.4
+ to 38.5+months) for ipilimumab-treated patients (n= 177),
with 76% of responses ongoing.
Median PFS was 2.8 months (95% CI 2.7–2.8) overall in patients
with mucosal melanoma, and 2.8 months for both ipilimumab-
naïve (2.8–3.0) and ipilimumab-treated (2.6–5.1) patients (Fig. 2a).
In nonmucosal melanoma, median PFS was 4.2 months (3.6–5.5)
overall, and 5.5 months (4.1–6.5) and 3.5 months (2.9–4.4) for
ipilimumab-naive and ipilimumab-treated patients (Fig. 2a). Med-
ian OS was 11.3 months (95% CI 7.7–16.6) overall in patients with
mucosal melanoma, and 14.0 months (6.1–24.3) and 10.2 months
(6.1–17.1), respectively, for ipilimumab-naive and ipilimumab-
treated patients. In nonmucosal melanoma, median OS was
23.5 months (21.1–26.8) overall, and 29.1 months (27.1–32.2) and
17.5 months (15.6–20.4), respectively, in ipilimumab-naive and
ipilimumab-treated patients (Fig. 2b).
Safety
Sixty-one of 84 (73%) patients with mucosal melanoma and
1203 of 1483 (81%) with nonmucosal melanoma had a treatment-
related adverse event (AE). Most treatment-related AEs were
low grade. Eight (10%) patients with mucosal melanoma and
263 (18%) with nonmucosal melanoma had a grade 3–4
treatment-related AE, and 3 (0.2%) patients with nonmucosal
Table 1 Baseline disease and patient characteristics
Characteristics, n (%) Mucosal
N= 84
Nonmucosal
N= 1483
P-valuec
Age, median (range), years 64 (15–87) 61 (18–94) 0.4805
≥65 years 41 (49%) 620 (42%) 0.2061
Women 48 (57%) 568 (38%) 0.0006
ECOG PS 1 27 (32%) 513 (35%) 0.6459
Elevated LDH 40 (48%) 537 (36%) 0.0349
BRAFV600 mutant 7 (8%) 427 (29%) <0.0001
M1c disease 68 (81%) 1102 (74%) 0.1732
Liver metastases 20 (24%) 286 (19%) 0.3089
Baseline tumour size ≥ 80.5
mma
49 (58%) 645 (43%) 0.0077
PD-L1 positiveb 46 (70%) 888 (77%) 0.1675
No. of prior systemic therapies
0 8 (10%) 150 (10%) 0.0462
1 31 (37%) 639 (43%) ─
2 38 (45%) 467 (31%) ─
≥3 7 (8%) 227 (15%) ─
Prior chemotherapy 18 (21%) 233 (16%) 0.1646
Prior ipilimumab 33 (39%) 666 (45%) 0.3131
ECOG eastern cooperative oncology group, LDH lactate dehydrogenase
aBaseline tumour size is the sum of the longest diameters of target lesion.
80.5 mm is the median in the total population
bPercentage is calculated using the number of patients with known PD-L1
status as the denominator (n= 66 for mucosal and 1152 for nonmucosal)
cBased on t-test for age and on chi-square test for other characteristics
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melanoma had a grade 5 treatment-related AE of general physical
deterioration, sepsis, and respiratory failure in one patient each
(Supplementary Table).
DISCUSSION
This post-hoc analysis showed that pembrolizumab provided
durable antitumour activity with clinically relevant benefit in
patients with advanced mucosal melanoma regardless of prior
ipilimumab. The ORR was 19% and median time to response was
2.8 months for patients with mucosal melanoma who received
pembrolizumab. Responses were similar among ipilimumab-naïve
and ipilimumab-treated patients. Consistent with previous reports,
responses were lower in patients with mucosal versus nonmucosal
melanoma (ORR 19% versus 33%), but appeared similarly
durable with 75% and 72% of patients, respectively, having an
ongoing response without progression. Although survival seemed
shorter in patients with mucosal versus nonmucosal melanoma
(median PFS of 2.8 months versus 4.2 months and median OS
of 11.3 months versus 23.5 months), the benefit in patients
with mucosal melanoma appeared clinically relevant. However,
longer follow-up will be needed to confirm that durable responses
translate into a higher proportion of patients achieving long-term
survival benefit.
Mucosal melanomas have strikingly different biologic and
molecular profiles compared with nonmucosal melanomas that,
in addition to differences in originating anatomic location, may
contribute to lower efficacy outcomes.10,11 In this study, a higher
proportion of patients with mucosal melanoma had elevated
LDH levels and overall baseline median tumour size ≥80.5 mm,
and fewer had BRAFV600 mutation compared to patients with
nonmucosal melanoma, all statistically significant differences. In
addition, ~45% and 31% of patients with mucosal and
nonmucosal melanoma had ≥2 prior therapies and 30% and
23%, respectively, were PD-L1 negative, characteristics asso-
ciated with lower efficacy in patients with advanced melanoma.9
However, comparison of outcomes between mucosal and
nonmucosal melanoma should be interpreted with caution
given the post-hoc nature of this analysis, differences in baseline
characteristics, and the small number of patients with mucosal
melanoma. Lack of anatomic information is an additional
limitation. Going forward, combination regimens may be of
greater benefit in mucosal melanoma.6 Ongoing studies of PD-1
inhibitors in mucosal melanoma include nivolumab and
ipilimumab (NCT02978443), and pembrolizumab and epacado-
stat (NCT02752074). In summary, as in nonmucosal melanoma,
pembrolizumab provided a durable antitumour benefit for
responding patients and is an effective treatment for advanced
mucosal melanoma.
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